Cisplatin-induced cardiotoxicity – two case reports
Journal Title: OncoReview - Year 2015, Vol 5, Issue 4
Abstract
Cisplatin has been used for over 40 years in various cancer chemotherapies. Toxicity induced by cisplatin-based therapeutic regimens include gastrointestinal toxicity, myelotoxicity, neurotoxicity, ototoxicity and nephrotoxicity. Cisplatin-based regimens have been associated with a wide range of cardiovascular complications. In this paper, we report 2 cases of cisplatin-induced cardiotoxicity. We present cases of 2 young patients who developed acute myocardial infarction during combination chemotherapy with bleomycin, etoposide and cisplatin. The first patient had acute anterior wall ST elevation myocardial infarction and the second one had acute myocardial infarction with peripheral arterial thromboembolism. Cisplatin use can result in cardiovascular events. Clinicians should be very cautious while managing patients on cisplatin-based chemotherapy.Early recognition of cardiotoxicity will allow for timely prevention of permanent cardiac damage.
Authors and Affiliations
Sheela Sawant, J. Prakruthi, Anuprita Daddi, Jaya Ghosh, Amit Joshi, Aruna Dhir
Role of recombinant human erythropoietin in the treatment of cancer-related anaemia
Anaemia is one of the most frequently diagnosed complications in cancer patients and also occurs during the course of cancer treatment. The condition can be observed in as many as 60–70% of patients who receive chemother...
Administration of liposomal doxorubicin in patients with metastatic breast cancer and significant concomitant cardiovascular conditions
A frequent dilemma faced by an oncologist about to take decision on a chemotherapeutic regime for patients with metastatic breast cancer is how to maintain balance between the expected treatment efficacy and predictable...
Toxicity profile of lapatinib plus capecitabine in advanced breast cancer – a single-centre follow-up study
Breast cancer is the most prevalent female neoplasm in Poland as well as in the rest of the world, accounting for 25% of all cancers. Lapatinib is a reversible inhibitor of the HE -1 and HER-2 tyrosine kinase receptors....
Ifosfamide-induced encephalopathy in a patient with metastatic fibrosarcoma
Ifosfamide is a cytostatic drug commonly used in chemotherapy. One of the common adverse effects resulting from the treatment with ifosfamide is encephalopathy. This paper describes a case study of a 64-year-old patient...
Original vs generic drugs in treatment of chronic myeloid leukaemia
The beginning of the twenty-first century saw a breakthrough in haematology, oncology and general medicine driven by the introduction of imatinib (Glivec) to the treatment of chronic myeloid leukaemia. For the first time...